Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

E. coli infection

Supported pathogenE. coliEscherichia coli

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “escherichia coli”, “e. coli”, “e.coli”, “e coli”, “e. coli infection”.

Laboratory measurements against E. coli recorded in ChEMBL.

Show all 76

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against E. coli that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

E. coli has 336 repurposing candidates in all. 6 are already listed above, with a registered study for this condition or a laboratory record, so the other 330 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for E. coli, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started14 of 14 have a start date · most in 2008 (3)
200520162026

  • Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli

    NCT07482553 · start 2026-05-01

    Registered record
    Registry ID
    NCT07482553
    Conditions
    Urinary Tract Infections (UTIs); Catheter-Associated Urinary Tract Infections (CAUTIs); Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)
    Interventions
    chitosan nanoparticles
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2027-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections (UTIs); Catheter-Associated Urinary Tract Infections (CAUTIs); Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)
    Interventionchitosan nanoparticles
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Cefotetan Therapy for Escherichia Coli Infections

    NCT07318584 · start 2026-03

    Registered record
    Registry ID
    NCT07318584
    Conditions
    E Coli Infection; ESBL Producing E.Coli
    Interventions
    Cefotetan; Carbapenems; Beta Lactam Antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2028-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection; ESBL Producing E.Coli
    InterventionCefotetan; Carbapenems; Beta Lactam Antibiotics
    PhasePhase 2
    Registry statusNot yet recruiting

  • Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

    NCT04574596 · start 2020-11-12

    Registered record
    Registry ID
    NCT04574596
    Conditions
    E Coli Infection
    Interventions
    no Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-12
    Completion
    2021-06-01
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionE Coli Infection
    Interventionno Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

    NCT03891433 · start 2019-04-01

    Registered record
    Registry ID
    NCT03891433
    Conditions
    Urinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem; Escherichia Coli Infection; Klebsiella Pneumoniae Infection; Clinical Trial; Drug Resistance, Bacterial
    Interventions
    Meropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2019-04-01
    Completion
    2026-04-01
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem +4 more
    InterventionMeropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    PhasePhase 4
    Registry statusSuspended

  • Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients

    NCT02729116 · start 2016-07

    Registered record
    Registry ID
    NCT02729116
    Conditions
    Anti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation; Urinary Tract Infections
    Interventions
    Sitafloxacin; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2024-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnti-Infective Agents, Urinary; Escherichia Coli Infections; Klebsiella Infections; Kidney Transplantation +1 more
    InterventionSitafloxacin; Ertapenem
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

    NCT02620007 · start 2015-12

    Registered record
    Registry ID
    NCT02620007
    Conditions
    Crohn Disease; Adherent-invasive E. Coli
    Interventions
    Ciprofloxacin; Rifaximin; Ciprofloxacin Placebo; Rifaximin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2022-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn Disease; Adherent-invasive E. Coli
    InterventionCiprofloxacin; Rifaximin; Ciprofloxacin Placebo; Rifaximin Placebo
    PhasePhase 2
    Registry statusTerminated

  • Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

    NCT02142751 · start 2014-07

    Registered record
    Registry ID
    NCT02142751
    Conditions
    Infection Due to ESBL Escherichia Coli
    Interventions
    Fosfomycin sodium intravenous; Meropenem intravenous; Ceftriaxone intravenous
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-07
    Completion
    2019-03
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to ESBL Escherichia Coli
    InterventionFosfomycin sodium intravenous; Meropenem intravenous; Ceftriaxone intravenous
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

    NCT01820793 · start 2013-05

    Registered record
    Registry ID
    NCT01820793
    Conditions
    Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
    Interventions
    Cefoxitin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2013-05
    Completion
    2015-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
    InterventionCefoxitin
    PhaseNot applicable
    Registry statusTerminated

  • Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli

    NCT02537847 · start 2012-11

    Registered record
    Registry ID
    NCT02537847
    Conditions
    Infection Due to Escherichia Coli; Acute Pyelonephritis
    Interventions
    Sitafloxacin; Ertapenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2016-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Escherichia Coli; Acute Pyelonephritis
    InterventionSitafloxacin; Ertapenem
    PhasePhase 2
    Registry statusUnknown

  • Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

    NCT00928200 · start 2009-04-13

    Registered record
    Registry ID
    NCT00928200
    Conditions
    Relapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli Asparaginase
    Interventions
    Erwinase; Vincristine; Dexamethasone; Doxorubicin; Cytarabine; Methotrexate; Triple Intrathecal Therapy; Dexrazoxane
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-04-13
    Completion
    2010-06-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Acute Lymphoblastic Leukemia; Allergy to PEG e.Coli Asparaginase; Allergy to Native e.Coli Asparaginase
    InterventionErwinase; Vincristine; Dexamethasone; Doxorubicin +4 more
    PhasePhase 1
    Registry statusTerminated

  • Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

    NCT00654108 · start 2008-06-02

    Registered record
    Registry ID
    NCT00654108
    Conditions
    Gastroenteritis Escherichia Coli
    Interventions
    Ciprofloxacin; Peru-15-pCTB; Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-06-02
    Completion
    2010-12-31
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroenteritis Escherichia Coli
    InterventionCiprofloxacin; Peru-15-pCTB; Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
    PhasePhase 1
    Registry statusCompleted

  • Enteroaggregative E.Coli (EAEC)

    NCT00362869 · start 2008-02

    Registered record
    Registry ID
    NCT00362869
    Conditions
    Escherichia Coli Infections
    Interventions
    Levofloxacin; Placebo; Enteroaggregative E. coli (EAEC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-02
    Completion
    2008-12
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEscherichia Coli Infections
    InterventionLevofloxacin; Placebo; Enteroaggregative E. coli (EAEC)
    PhasePhase 1
    Registry statusTerminated

  • Ampicillin-sulbactam Resistant E.Coli at UPMC

    NCT00619580 · start 2008-02

    Registered record
    Registry ID
    NCT00619580
    Conditions
    Positive E Coli Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2008-02
    Completion
    2014-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPositive E Coli Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

    NCT00167999 · start 2005-02

    Registered record
    Registry ID
    NCT00167999
    Conditions
    Gram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventions
    piperacillin-tazobactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-02
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Escherichia Coli Infections; Klebsiella Infections
    Interventionpiperacillin-tazobactam
    PhaseNot recorded
    Registry statusCompleted